Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 15/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 2/20 | 0.36 |
| ▸ | CLPP | Q16740 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12037786 | 0.94 | CYP3A4 (0.38) | CYP3A4CNR1CNR2CLPP | |
| SCHEMBL12037523 | 0.94 | CYP3A4 (0.38) | CYP3A4CNR1CNR2CLPP | |
| SCHEMBL10225116 | 0.93 | CYP3A4 (0.35) | ALDH1A1CYP3A4METAP2 | |
| SCHEMBL746225 | 0.92 | ALDH1A1 (0.37) | ALDH1A1CYP3A4CNR1CNR2METAP2 | |
| SCHEMBL14620131 | 0.91 | CYP3A4 (0.38) | ALDH1A1CYP3A4CLPP | |
| SCHEMBL14620549 | 0.90 | CYP3A4 (0.39) | CYP3A4CLPP | |
| SCHEMBL747737 | 0.89 | METAP2 (0.39) | ALDH1A1CYP3A4CNR2METAP2 | |
| SCHEMBL749035 | 0.89 | METAP2 (0.39) | ALDH1A1CYP3A4CNR2METAP2 | |
| SCHEMBL747747 | 0.88 | ALDH1A1 (0.38) | ALDH1A1CYP3A4METAP2 | |
| SCHEMBL762843 | 0.88 | ALDH1A1 (0.35) | ALDH1A1CYP3A4METAP2CLPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120758-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2010-05-13 | — | — | US | disclosed |
| US-20100081655-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2010-04-01 | — | — | US | disclosed |
| US-20100029630-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | Chongwae Pharma Corporation (KR) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029630-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | ALDH1A1 4305/4885CYP3A4 4757/4885CNR1 2719/4885 |
| US-20100120758-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | ALDH1A1 4305/4885CYP3A4 4757/4885CNR1 2719/4885 |
| US-20100081655-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | ALDH1A1 4305/4885CYP3A4 4757/4885CNR1 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.